

RE: FOI 24/365 PL for Ethyol 375mg Ethyol 500mg

Tue 07/05/2024 16:34

To

Dear

Thank you for your enquiry.

The marketing authorisation details for this product are as follows:

PL 33505/0001 ETHYOL (AMIFOSTINE) 500MG/VIAL PINNACLE BIOLOGICS BV

(previously PL 11284/0004 held by MEDIMMUNE ONCOLOGY INCORPORATED)

Granted: 23/11/1994

This licence included the 500mg and 375mg vials. The marketing authorisation has subsequently been cancelled.

Communications and Engagement
Medicines and Healthcare Products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU
Telephone: 020 3080 6000
Email: info@mhra.gov.uk
gov.uk/mhra
[Stay connected](#)

From: [REDACTED]
Sent: Wednesday, April 17, 2024 4:48 PM
To: MHRA Customer Services <MHRACustomerServices@mhra.gov.uk>
Cc: [REDACTED]
Subject: FOI 24/365 PL for Ethyol 375mg Ethyol 500mg

Dear MHRA Freedom of Information Team,

I am trying to find the PL number for the below two products which I believe were first approved in 1996 but have since been discontinued. Could you please provide me with the product license details for these 2 products?

Ethyol 375mg: [Actual Medicinal Product pack \(AMPP\) - Ethyol 375mg powder for solution for infusion vials 5 vial](#) Schering-Plough Ltd - dm+d browser (nhsbsa.nhs.uk)

Ethyol 500mg: [Actual Medicinal Product pack \(AMPP\)](#) - Ethyol 500mg powder for solution for infusion vials 3 vial Schering-Plough Ltd - dm+d browser (nhsbsa.nhs.uk)

Kind regards,

[REDACTED]

[REDACTED]
[REDACTED]

[REDACTED]

[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]
[REDACTED]

[REDACTED]

[REDACTED]

DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click [DHTermsAndConditions](#)

DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click [DHTermsAndConditions](#)